CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

BioPharma Dive
Original article

Scribe secures $129M in a rare gene editing IPO

IPO/OfferingPositive
AI Analysis

Summary

Scribe has secured $129M in an IPO, marking the first gene editing company to price an IPO in over two years, though raising significantly less than typical 2026 biotech IPOs.

Importance:7/10
Sentiment:
0.60
IPOgene editingcapital raise
Related Companies

Read the original article

Published by BioPharma Dive on July 24, 2026 1:18 AM

Read Original